Caregiver-Guided Pain Management Training in Palliative Care

Status Completed

Clinical Trial Summary

The purpose of this study is to develop more effective ways to help patients and their caregivers cope with cancer pain. The investigators are looking at the usefulness of a Caregiver-Guided Pain Management Training Intervention versus Pain Education.

Clinical Trial Description

The primary aim of this study is to test the efficacy for the Caregiver-Guided Pain Management Training intervention to improve the caregiver's self-efficacy for helping the patient manage pain. Secondary aims include testing the effectiveness of the CG-PMT intervention to improve patient pain severity, patient self-efficacy for pain management and patient psychological distress, as well as short-term caregiver adjustment and caregiver adjustment following the patient's death. In this multi-site study, 236 dyads (patients with cancer pain and their family caregivers) will be randomized to either a Caregiver-Guided Pain Management Training protocol or to an Enhanced Treatment-as-Usual control condition. Dyads in the Caregiver-Guided Pain Management condition will receive three one-hour sessions conducted via videoconference. Dyads in the Enhanced Treatment-as-Usual condition will receive educational material about cancer pain and its management but will not receive any study-related treatment sessions. Assessments will be conducted with patients and caregivers before and after treatment, and with caregivers 3 months and 6 months following the patient's death. The primary hypothesis to be tested is that caregivers who receive the intervention will report significantly higher levels of self-efficacy for helping the patient manage pain than caregivers in the control condition. Secondary aims will focus on (a) improvements in short-term caregiver adjustment as well as caregiver adjustment following the patient's death, and (b) patient pain severity, self-efficacy for pain management, and psychological distress. ;

Study Design

Related Conditions & MeSH terms

Advanced Cancer

Clinical Trial Details

NCT number	NCT02430467
Study type	Interventional
Source	Duke University
Contact
Status	Completed
Phase	N/A
Start date	July 2015
Completion date	October 4, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03181854` - Randomized Controlled Trial of Integrated Early Palliative Care	N/A
Completed	`NCT01197170` - Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance	Phase 1
Recruiting	`NCT05045040` - Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions	N/A
Active, not recruiting	`NCT05060432` - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors	Phase 1/Phase 2
Active, not recruiting	`NCT03994601` - An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers	Phase 1/Phase 2
Active, not recruiting	`NCT03667716` - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.	Phase 1
Completed	`NCT01393990` - A Study of LY2228820 in Participants With Advanced Cancer	Phase 1
Completed	`NCT02857270` - A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer	Phase 1
Recruiting	`NCT03175224` - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	Phase 2
Active, not recruiting	`NCT04121676` - Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer	Phase 1
Active, not recruiting	`NCT03177291` - Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC	Phase 1
Completed	`NCT03980041` - Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)	Phase 2
Active, not recruiting	`NCT03674567` - Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab	Phase 1/Phase 2
Recruiting	`NCT04823377` - Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.	N/A
Completed	`NCT02778126` - A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer	Phase 1
Completed	`NCT02507544` - A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer	Phase 1
Completed	`NCT02529553` - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer	Phase 1
Completed	`NCT02245204` - Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers	Phase 1
Terminated	`NCT01929941` - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies	Phase 1
Completed	`NCT01583777` - Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer	Phase 1